Skip to content
ENKO

Precision Oncology Pipeline

Transforming spatial insights into life-changing, de-risked therapeutic assets. We build highly valuable ADCs and RPTs ready for rapid clinical advancement.

OVERVIEW

Discovery programs at a glance

PROGRAMMODALITYTARGETDISCOVERYIN-VITROIN-VIVOPRE-CLINICAL
POR001ADCUndisclosed
Progressed to Pre-clinical
POR003ADCUndisclosed
In-vitro validation complete
POR006RPTUndisclosed
Entering human imaging
POR-TBD-AADCUndisclosed
Target discovery ongoing

DEEP DIVE

Discovery programs

LEAD ASSET · ADC

POR001: Mastering the tumor–immune interface

Designed for optimal immune-activating payload delivery (TLR7/8, STING agonists). Spatial transcriptomics analysis demonstrates POR001's significantly higher co-localization with T-cell activation zones compared to conventional targets like TROP2 and HER2.

  • 43% higher co-localization with immune-active regions
  • Optimal for treating immune-cold tumor cores
  • IND-enabling studies underway
POR001 mechanism diagram - placeholder TROP2 / HER2 POR001 TARGET + T-CELL
LEAD ASSET · ADC

POR003: Optimizing the ADC delivery to tumor

POR003 uses Portrai's spatial PK framework to select a target with superior tissue-wide distribution compared to standard CEACAM5-class ADCs. Placeholder copy pending BD review.

  • Broader intra-tumoral distribution vs. CEACAM5 benchmark
  • Expanding to GI oncology indications
POR003 mechanism diagram - placeholder CEACAM5 POR003 TME-PK
NEXT-GEN · RPT

POR006: Precision radiation delivery

Advancing rapidly through our Validation Framework. POR006 leverages our proprietary spatial insights to ensure ultra-precise delivery of radiopharmaceuticals, currently progressing towards advanced pre-clinical and human imaging stages.

  • Advancing to human imaging stages
  • Highly selective biodistribution profile
POR006 mechanism diagram - placeholder IN-VIVO · RPT BIODISTRIBUTION

PARTNERSHIP

Partner with Portrai for early out-licensing

Portrai's pipeline assets are validated with spatial biology and AI-driven insights. We are seeking strategic partnerships to accelerate clinical development.

Co-Discovery

Leverage Portrai's platform to find novel targets for your specific modalities.

Asset Licensing

Access pre-clinical POR-series assets on a path toward IND-enabling studies.

Modality Expansion

Parallel validation for ADCs, RPTs, and T-cell engagers.

LET'S TALK

Ready to accelerate your oncology pipeline?

Connect with our Business Development team to discuss licensing opportunities, view confidential data rooms, or explore co-discovery partnerships.

Contact BD Team